Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression
- 1 April 2003
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 12 (2), 137-144
- https://doi.org/10.1034/j.1600-0625.2003.120203.x
Abstract
Whereas the effects of interleukin (IL)‐10 on several epithelial cell types are well established the capability of IL‐10 to target keratinocytes (KC) is still a matter of debate. This, however, is of considerable importance, as IL‐10 is a major anti‐inflammatory, immunosuppressive cytokine with impact on the cutaneous homeostasis. Recently, IL‐10 therapy has been proven to be clinically effective in psoriasis. Response to therapy is associated with normalization of typical parameters of keratinocyte pathology, but it is unclear whether this results from direct or indirect (secondary) effects. The purpose of the present study was to further investigate direct effects of IL‐10 on keratinocytes and to address the reason for potential IL‐10 unresponsiveness using keratinocytes such as the cell line HaCaT as well as primary foreskin keratinocytes. Using real time RT‐PCR we demonstrated that IL‐10 is neither able to induce its typical early gene product suppressor of cytokine signalling (SOCS) 3 nor to modulate the interferone (IFN)‐γ‐induced expression of SOCS 1 and 3. Although flow cytometric analyses showed binding of biotin labelled IL‐10 to HaCaT cells, blocking experiments indicated that this resulted from unspecific binding. Moreover, scatchard plot analyses excluded specific binding to primary KC and HaCaT cells. Finally, real time mRNA analyses and Western blot experiments demonstrated that the absence of any specific binding results from the absence of clear IL‐10R1 (alpha chain) expression, whereas the IL‐10R2 (beta chain) is strongly expressed. Our data indicates that IL‐10 unresponsiveness of keratinocytes could be explained by the lacking of functional IL‐10 receptor expression and suggest that any IL‐10 effects on these cells observed are indirectly mediated.Keywords
This publication has 19 references indexed in Scilit:
- Immunomodulation by Interleukin-10 Therapy Decreases the Incidence of Relapse and Prolongs the Relapse-free Interval in PsoriasisJournal of Investigative Dermatology, 2002
- Effects of Systemic Interleukin-10 Therapy on Psoriatic Skin Lesions: Histologic, Immunohistologic, and Molecular Biology FindingsJournal of Investigative Dermatology, 2001
- Interleukin-10 and the Interleukin-10 ReceptorAnnual Review of Immunology, 2001
- Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte MaturationJournal of Investigative Dermatology, 2001
- The treatment of psoriasis with IL-10: rationale and review of the first clinical trialsExpert Opinion on Investigational Drugs, 2000
- IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.Journal of Clinical Investigation, 1998
- Interleukin‐10 inhibits IgE‐mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytesEuropean Journal of Immunology, 1995
- Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta.The Journal of Experimental Medicine, 1995
- Up-Regulation of Keratin 17 Expression in Human HaCaT Keratinocytes by Interferon-γJournal of Investigative Dermatology, 1995
- Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.The Journal of cell biology, 1988